BioSpace News Archive

Oral presentation of ASPIRO results to include additional efficacy and safety data on all patients in dose Cohort 1 and the first treated patients in dose Cohort 2

Medable Inc., leading the transformation of clinical trials with a digital trials platform connecting patients, sites, and clinical trial teams, will demonstrate a number of integrated eClinical, telemedicine, and data management solutions at the 2019 Society of Clinical Data Management Annual Conference, booth #607, September 29 – October 2 in Baltimore, Maryland.

Sunovion’s support services program is recognized by J.D. Power for providing an outstanding customer service experience

Oncopeptides AB announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incentive programs.

Moderna, Inc. announced the U.S. Food and Drug Administration has completed their review of the Investigational New Drug application for mRNA-3927, its investigational mRNA therapeutic for propionic acidemia and allowed it to proceed to clinic.

Repro Med Systems, Inc. dba RMS Medical Products announced that R. John Fletcher has been appointed Chairman of the Board.

Funding will support clinical development of stem cell-derived platelet technology platform

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, is proud to welcome Joshuaine Grant as Senior Principal Scientist.

After a series of large-scale food safety problems almost a decade ago, Congress passed the U.S. Food and Drug Administration Food Safety Modernization Act, or FSMA, to shift our food safety system from one that focused primarily on responding to problems to a system that prevents them from happening in the first place.

Aprecia, the 3DP Pharmaceutical Company, today announced that Lynda Harker, RPh, will lead the company’s national sales team to accelerate the promotion of SPRITAM® (levetiracetam) Tablets for Oral Suspension, an adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures for patients with certain types of epilepsy